ArticleMedical hypotheses2020
Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities.
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 59 citations in OpenAlex.
- Age-Specific Seroprevalence of Hepatitis A Virus in Turkey Between 2000 and 2023: Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2024Review
- Symptomatic MERS-CoV infection reduces the risk of future COVID-19 disease; a retrospective cohort study.BMC infectious diseases · 2023Article
- Retrospective Comparison of Nigeria's Emergency Response Between the 2014 Ebola Outbreak and 2020 COVID-19 Pandemic.Cureus · 2023Review
- Impact of MERS-CoV and SARS-CoV-2 Viral Infection on Immunoglobulin-IgG Cross-Reactivity.Vaccines · 2023Article
- The two-stage molecular scenery of SARS-CoV-2 infection with implications to disease severity: An in-silico quest.Frontiers in immunology · 2023Article
- Article
- Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.Lancet (London, England) · 2022Article
- Article
- Is There A Correlation Between COVID-19 and Hepatitis A and Hepatitis E Serum Antibody Level?Iranian journal of pathology · 2022Article
- How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.The Journal of general virology · 2021Article
- Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021Article
- Immunomodulation and immunotherapeutics of COVID-19.Clinical immunology (Orlando, Fla.) · 2021Review
- Article
- A look into the future of the COVID-19 pandemic in Europe: an expert consultation.The Lancet regional health. Europe · 2021Review
- The Potential of Developing Pan-Coronaviral Antibodies to Spike Peptides in Convalescent COVID-19 Patients.Archivum immunologiae et therapiae experimentalis · 2021Article
- COVID-19: cross-immunity of viral epitopes may influence severity of infection and immune response.Signal transduction and targeted therapy · 2021Article
- COVID-19 in a case previously infected with MERS-CoV: No cross immunity.The Journal of infection · 2021Article
- The impact of COVID-19 on Old World Camelids and their potential role to combat a human pandemic.Animal frontiers : the review magazine of animal agriculture · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Of the seven coronaviruses associated with disease in humans, SARS-CoV, MERS-CoV and SARS-CoV-2 cause considerable mortality but also share significant sequence homology, and potentially antigenic epitopes capable of inducing an immune response. The degree of similarity is such that perhaps prior exposure to one virus could confer partial immunity to another. Indeed, data suggests a considerable amount of cross-reactivity and recognition by the hosts immune response between different coronavirus infections. While the ongoing COVID-19 outbreak rapidly overwhelmed medical facilities of particularly Europe and North America, accounting for 78% of global deaths, only 8% of deaths have occurred in Asia where the outbreak originated. Interestingly, Asia and the Middle East have previously experienced multiple rounds of coronavirus infections, perhaps suggesting buildup of acquired immunity to the causative SARS-CoV-2 that underlies COVID-19. This article hypothesizes that a causative factor underlying such low morbidity in these regions is perhaps (at least in part) due to acquired immunity from multiple rounds of coronavirus infections and discusses the mechanisms and recent evidence to support such assertions. Further investigations of such phenomenon would allow us to examine strategies to confer protective immunity, perhaps aiding vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.